Category: Parkinson's Disease: Cognitive functions
Objective: To characterise the cognitive decline of patients with neurodegenerative disorders: Parkinson’s disease (PD), Alzheimer’s disease (AD) and essential tremor (ET) and to compare their neuropsychological profiles.
Background: Cognitive impairments are frequently follows the neurodegenerative disorders like PD, AD and ET, but risk factors of cognitive impairments and cognitive declines are still undetermined clearly. We have identified the cognitive domains that are most sensitive to mild deficits of cognitive functions of patients with neurodegenerative disorders and selected factors most impacting on cognitive functions.
Method: Study based on data collected from 423 patients with neurodegenerative disorders (83 patients with ET, 224 patients with PD, 116 patients with AD) and 96 healthy control (HC). All subjects are passed neuropsychological and clinical assessment, daily functioning was evaluated by ADL/IADL. To detect and calculate the prevalence of cognitive impairment, discriminating cognitive profiles and disease-stage we’ve used MoCA test. Global cognitive status (MoCA) was divided into five cognitive domains: executive, memory, attention, visuospatial and language abilities. Statistical testing was done in SPSS 24 software using Chi-square test and student t-test.
Results: It was identified that PD and AD patients has lower score of cognitive function (p<0,05), AD patients has attentive and memory deficits (p<0,05), PD patients cognitively declined in attention/executive and visuospatial tasks (p<0,05), and MoCA total score was significantly lower for AD and PD patient than for ET and HC (p<0,05). Moreover, investigating groups of PD, AD, ET and HC patients we found strong specific patterns of cognitive declines.
Conclusion: Cognitive impairments of patients with neurodegenerative disorders are differentiated by cognitive domains. Different risk factors of cognitive impairments and cognitive declines can influence on cognitive functions of patients with neurodegenerative disorders. Knowing these risk factors we can effectively protect and treat cognitive impairments of patients with neurodegenerative disorders.
To cite this abstract in AMA style:
I. Zhukova, E. Kolupaeva, N. Zhukova, O. Izhboldina, M. Nikitina, A. Latipova, S. Shtaymets, I. Mironova, Z.h Kislukhina, L. Tkachenko, A. Agasheva, D. Novotnyy. Cognitive profiling of patients with neurodegenerative disorders [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/cognitive-profiling-of-patients-with-neurodegenerative-disorders/. Accessed November 10, 2026.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/cognitive-profiling-of-patients-with-neurodegenerative-disorders/